# A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

> **NCT04444167** · PHASE1,PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 59 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AK104
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04444167
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444167, "A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04444167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*